- Home
- SFL vs NVAX Comparison
SFL vs NVAX Comparison
Compare SFL & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- NVAX
- Stock Information
- Founded
- SFL 2003
- NVAX 1987
- Country
- SFL Bermuda
- NVAX United States
- Employees
- SFL N/A
- NVAX N/A
- Industry
- SFL Marine Transportation
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SFL Consumer Discretionary
- NVAX Health Care
- Exchange
- SFL Nasdaq
- NVAX Nasdaq
- Market Cap
- SFL 1.1B
- NVAX 1.3B
- IPO Year
- SFL N/A
- NVAX 1995
- Fundamental
- Price
- SFL $8.87
- NVAX $7.12
- Analyst Decision
- SFL Strong Buy
- NVAX Buy
- Analyst Count
- SFL 1
- NVAX 5
- Target Price
- SFL $13.00
- NVAX $16.60
- AVG Volume (30 Days)
- SFL 1.3M
- NVAX 5.1M
- Earning Date
- SFL 08-13-2025
- NVAX 08-07-2025
- Dividend Yield
- SFL 12.08%
- NVAX N/A
- EPS Growth
- SFL N/A
- NVAX N/A
- EPS
- SFL 0.41
- NVAX 2.97
- Revenue
- SFL $852,590,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- SFL N/A
- NVAX $56.85
- Revenue Next Year
- SFL $3.20
- NVAX N/A
- P/E Ratio
- SFL $22.03
- NVAX $2.37
- Revenue Growth
- SFL 6.58
- NVAX 25.92
- 52 Week Low
- SFL $6.78
- NVAX $5.01
- 52 Week High
- SFL $14.05
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- SFL 57.60
- NVAX 57.25
- Support Level
- SFL $8.21
- NVAX $6.54
- Resistance Level
- SFL $9.07
- NVAX $6.90
- Average True Range (ATR)
- SFL 0.22
- NVAX 0.29
- MACD
- SFL 0.03
- NVAX 0.06
- Stochastic Oscillator
- SFL 76.74
- NVAX 92.52
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.